Robert Green: Newborn Sequencing Is the Goal Here in the U.S.

Robert Green, Professor at Harvard, Geneticist, Director, Genomes2People Research Program

Bio and Contact Info


0:00 Genomes2People - Accelerating the use of genomics in day-to-day practice of medicine

5:58 Medseq - How would WGS be used by regular doctors?

13:37 Is there a tension between democratization of genomics and science?

28:53 Who’s doing the PR?

31:17 Newborn sequencing the goal

"If you go to a scientific meeting, even with the greatest critics, and you ask, how many people in this audience believe that your entire genome will be part of your everyday medical care in fifty years, every person will raise their hand. So the only questions we’re debating are: how do we get there, how soon can we get there, and what evidence base must we have in place before we get there? What’s really exciting to me is getting there sooner rather than later. If we get there 20 years sooner, we are saving thousands of people's lives.”

That’s today’s guest, Robert Green, Professor of Medicine at Harvard Medical School and a physician-scientist who directs the Genomes2People Research Program at Brigham and Women’s Hospital, the Broad Institute, and Ariadne Labs. It's with this program that Robert and his team have led the MedSeq and BabySeq studies.

Robert says when he first announced BabySeq, a study to do whole genome sequencing for thousands of newborns, there was a lot of push back in the community. Is there a built-in tension between his desire to democratize genomic information on the one hand and to do clinical trials on the other? We ask him this and many more questions in a show that pulls back the curtain on the latest efforts to bring whole genome sequencing into the day-to-day practice of medicine.

Customize This

New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup